Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of “Buy” by Brokerages

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have received a consensus rating of “Buy” from the three brokerages that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $20.00.

A number of brokerages recently issued reports on FOLD. Cantor Fitzgerald reiterated an “overweight” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a research report on Thursday, February 29th. JPMorgan Chase & Co. cut their target price on Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Monday, March 18th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday. Finally, Bank of America decreased their price objective on Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Friday.

Insider Transactions at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 4,167 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $14.00, for a total transaction of $58,338.00. Following the transaction, the chief executive officer now owns 871,219 shares of the company’s stock, valued at approximately $12,197,066. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Chairman John F. Crowley sold 31,614 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $13.81, for a total value of $436,589.34. Following the completion of the sale, the chairman now owns 697,628 shares in the company, valued at $9,634,242.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bradley L. Campbell sold 4,167 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total value of $58,338.00. Following the completion of the transaction, the chief executive officer now directly owns 871,219 shares of the company’s stock, valued at approximately $12,197,066. The disclosure for this sale can be found here. Insiders have sold a total of 55,208 shares of company stock worth $732,930 in the last 90 days. 2.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Amicus Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Vontobel Holding Ltd. acquired a new stake in shares of Amicus Therapeutics during the 4th quarter worth about $1,173,000. Envestnet Asset Management Inc. raised its stake in shares of Amicus Therapeutics by 170.6% during the third quarter. Envestnet Asset Management Inc. now owns 393,728 shares of the biopharmaceutical company’s stock worth $4,788,000 after buying an additional 248,220 shares during the last quarter. O Shaughnessy Asset Management LLC raised its stake in shares of Amicus Therapeutics by 25.3% during the third quarter. O Shaughnessy Asset Management LLC now owns 15,243 shares of the biopharmaceutical company’s stock worth $185,000 after buying an additional 3,082 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Amicus Therapeutics by 0.4% during the third quarter. Vanguard Group Inc. now owns 27,131,873 shares of the biopharmaceutical company’s stock worth $329,924,000 after buying an additional 107,456 shares during the last quarter. Finally, MPM Bioimpact LLC raised its stake in shares of Amicus Therapeutics by 38.7% during the third quarter. MPM Bioimpact LLC now owns 716,139 shares of the biopharmaceutical company’s stock worth $8,708,000 after buying an additional 200,000 shares during the last quarter.

Amicus Therapeutics Stock Performance

Amicus Therapeutics stock opened at $9.48 on Friday. Amicus Therapeutics has a 12 month low of $9.24 and a 12 month high of $14.57. The company has a fifty day moving average price of $11.29 and a two-hundred day moving average price of $11.96. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.88 and a quick ratio of 2.52. The company has a market cap of $2.81 billion, a PE ratio of -18.59 and a beta of 0.80.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. The firm had revenue of $115.08 million for the quarter, compared to analyst estimates of $115.11 million. Research analysts expect that Amicus Therapeutics will post 0.01 earnings per share for the current year.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.